Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISC-0974 in Non-Dialysis Dependent Chronic Kidney Disease and Anemia
NCT05745883Phase 1Completed
- Sponsor
- Disc Medicine
- Start
- Apr 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selcodebart in anemia of chronic kidney disease (CKD-A) (4 arms), sponsored by Disc Medicine. Primary endpoints: Incidence of treatment-emergent adverse events up to 145 days, Incidence of clinically abnormal vital signs up to 145 days and 3 more. Started Apr 2023; status: completed.
02
Drugs
selcodebart
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT05745883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745883.